CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update
by Tristan Rich · The Markets DailyCNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Get Free Report) was the recipient of a large drop in short interest in the month of August. As of August 31st, there was short interest totaling 2,193 shares, a drop of 82.6% from the August 15th total of 12,595 shares. Based on an average daily volume of 10,393 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.2% of the company’s stock are short sold.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of CNSP. Boothbay Fund Management LLC bought a new stake in shares of CNS Pharmaceuticals during the 4th quarter worth approximately $71,000. Stonepine Capital Management LLC bought a new position in shares of CNS Pharmaceuticals in the second quarter valued at $198,719. Ikarian Capital LLC acquired a new position in CNS Pharmaceuticals during the fourth quarter worth $241,000. Armistice Capital LLC acquired a new position in CNS Pharmaceuticals during the second quarter worth $335,000. Finally, ADAR1 Capital Management LLC bought a new stake in CNS Pharmaceuticals during the second quarter worth $335,000. 14.02% of the stock is currently owned by institutional investors.
CNS Pharmaceuticals Price Performance
NASDAQ:CNSP traded down $0.02 on Friday, hitting $5.73. 3,338 shares of the company’s stock were exchanged, compared to its average volume of 529,154. The firm has a 50-day moving average price of $5.43 and a 200-day moving average price of $4.35. CNS Pharmaceuticals has a 52 week low of $1.90 and a 52 week high of $10.59. The company has a market cap of $8.37 million, a P/E ratio of -0.24 and a beta of 3.06.
CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.14).
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, CNS Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $20.00.
View Our Latest Report on CNS Pharmaceuticals
About CNS Pharmaceuticals
CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.
Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.